James D. Merselis

Chairman of the Board

James D. Merselis joined the board of Trinity Biotech (NASDAQ-GS:TRIB) in February 2009 as a non-executive director.  He is a Director of Biosensia Ltd; a pre-commercial, point-of-care diagnostics company located in Dublin, Ireland. In addition, he is Chairman of Abram Scientific Inc., point-of-care, coagulation monitoring company located in California.  Mr. Merselis has more than thirty-nine years experience in healthcare, with the first twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics).  Mr. Merselis has led a number of healthcare diagnostic start-ups.  From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin.  During this time he successfully took the company public (NASDAQ:HEM) followed two years later by its acquisition by Alere (NYSE:ALR).  His leadership at other start-ups has included: Nexus Dx (now Samsung), Alverix, Inc. (now Becton Dickenson), and Micronics, Inc. (now SONY).